Genetics, CRISPR and Medical Ethics: CEO of Synthego, CRISPR Therapeutics and Stanford Medical's Hurlbut at Healthy Returns
Genomic medicine's progress and future potential is hugely exciting, but it comes with enormous ethical implications. So how can we ensure its responsible use? CNBC's Meg Tirrell sits down with Synthego CEO Paul Dabrowski, CEO, Standford Medical School's Dr. William Hurlbut and CRISPR Therapeutics CEO Dr. Samarth Kulkarni.
Thu, May 23 201911:43 AM EDT